ISSN: 1044-579X
Journal Home
Journal Guideline
Seminars in Cancer Biology Q1 Unclaimed
Seminars in Cancer Biology is a journal indexed in SJR in Cancer Research with an H index of 179. It has a price of 2840 €. It has an SJR impact factor of 3,297 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 3,297.
Seminars in Cancer Biology focuses its scope in these topics and keywords: role, nuclear, cancer, natural, molecular, microrna, mechanismsthe, malignancy, lymphomagenesisa, inflammation, ...
Type: Journal
Type of Copyright:
Languages: English
Open Access Policy: Open Choice
Type of publications:
Publication frecuency: -
2840 €
Inmediate OANPD
Embargoed OA0 €
Non OAMetrics
3,297
SJR Impact factor179
H Index96
Total Docs (Last Year)745
Total Docs (3 years)17871
Total Refs9343
Total Cites (3 years)714
Citable Docs (3 years)11.64
Cites/Doc (2 years)186.16
Ref/DocOther journals with similar parameters
Signal Transduction and Targeted Therapy Q1
Molecular Cancer Q1
JAMA oncology Q1
Cell Host and Microbe Q1
Journal of Hematology and Oncology Q1
Compare this journals
Aims and Scope
Best articles by citations
Epstein-Barr virus and gastric carcinoma
View moreDefinition of tumor antigens suitable for vaccine construction
View moreTranslating mesothelioma molecular genomics and dependencies into precision oncology-based therapies
View moreChemokines in neuroectodermal development and their potential implication in cancer stem cell-driven metastasis
View moreA broad-spectrum integrative design for cancer prevention and therapy: The challenge ahead
View moreChemokines in neuroectodermal tumour progression and metastasis
View moreGenomic stability and tumorigenesis
View moreOncogenes and tumor angiogenesis
View moreOncogenes as therapeutic targets
View moreInteractions between adenovirus proteins and the p53 pathway: the development of ONYX-015
View moreOncogenic growth factor receptors: implications for signal transduction therapy
View moreCurrent criteria to establish human carcinogens
View morePutative role of 67 kDa elastin-laminin receptor in tumor invasion
View moreFusion oncogenes and tumor type specificity - insights from salivary gland tumors
View moreMinimal residual disease (MRD) in follicular lymphoma in the era of immunotherapy with rituximab
View moreFamilial nasopharyngeal carcinoma
View moreRegulating the regulators or how to elicit an immune response
View moreEpigenetic and proteolytic inactivation of 14-3-3s in breast and prostate cancers
View moreHepatitis C virus and its pathogenesis
View moreAGEs, RAGEs and s-RAGE; friend or foe for cancer
View moreIntroduction and overview
View moreWhere is the biology of CLL leading us?
View moreImplication of direct host-tumor intercellular interactions in non-immune host resistance to neoplastic growth
View moreCyclin E as a prognostic and predictive marker in breast cancer
View more
Comments